{"contentid": 488738, "importid": NaN, "name": "Positive top-line results from Phase III PRINCE study of pegcetacoplan in PNH", "introduction": "Positive top-line results have been reported from the Phase III PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment na\u00c3\u00afve.", "content": "<p>Positive top-line results have been reported from the Phase III PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment na&iuml;ve, meaning they had not received a complement inhibitor within three months before entering the study.</p>\n<p>The drug was originated by US biopharma company Apellis Pharmaceuticals (Nasdaq: APLS) and licensed to Swedish Orphan Biovitrum (STO: SOBI; also known as Sobi) for exclusive ex-US commercialization under a deal that provided a $250 million upfront payment plus eligibility for a further $1.25 billion for the US firm.</p>\n<p>Pegcetacoplan, which was approved in the USA under the trade name Empaveli earlier this month and with a European decision expected shortly, demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at week 26.</p>\n<ul>\n<li>86% of pegcetacoplan treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care (p&lt;0.0001). Hemoglobin stabilization was defined as an avoidance of a &gt;1 g/dL decrease in hemoglobin levels in the absence of transfusions.</li>\n<li>Mean LDH in the pegcetacoplan group decreased by 90% from a baseline of 2151 U/L [9.5x upper limit of normal (ULN)] to 211 U/L, which is within the normal range, compared to a 14% reduction on standard of care from a baseline of 1946 U/L (8.6x ULN) to 1681 U/L (7.4x ULN) (p&lt;0.0001).</li>\n</ul>\n<p>&ldquo;The positive PRINCE data showed that pegcetacoplan provided clinically-meaningful improvements across multiple measures that are important for patients and build on our recent FDA approval of pegcetacoplan in PNH,&rdquo; said Dr Federico Grossi, chief medical officer, Apellis. &ldquo;Combined with previous studies, these results emphasize the potential of pegcetacoplan to provide disease control for all adults with PNH regardless of prior treatment,&rdquo; he noted.</p>\n<h2><strong>Secondary endpoints also met</strong></h2>\n<p>Pegcetacoplan also achieved statistical superiority on several secondary endpoints, including improvements in hemoglobin levels and transfusion avoidance, compared to standard of care, which did not include complement inhibitors.</p>\n<ul>\n<li>Mean hemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from a baseline of 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019).</li>\n<li>91% of patients on pegcetacoplan were transfusion free compared to 22 per cent on standard of care (p&lt;0.0001).</li>\n</ul>\n<p>&ldquo;The PRINCE study results reinforce the efficacy and safety profile of pegcetacoplan in PNH,&rdquo; said Ravi Rao, head of R&amp;D and chief medical officer at Sobi, adding: &ldquo;Our hope is to contribute to an improvement of care, and to make a difference in the lives of people with this rare blood disease.&rdquo;</p>", "date": "2021-05-25 16:42:00", "meta_title": "Positive top-line results from Phase III PRINCE study of pegcetacoplan", "meta_keywords": "Apellis Pharma, Swedish Orphan Biovitrum, Pegcetacoplan, Empaveli, PNH, Paroxysmal, Nocturnal hemoglobinuria, Phase III", "meta_description": "Positive top-line results from Phase III PRINCE study of pegcetacoplan in PNH", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-25 16:41:51", "updated": "2021-05-25 16:50:41", "access": NaN, "url": "https://www.thepharmaletter.com/article/positive-top-line-results-from-phase-iii-prince-study-of-pegcetacoplan-in-pnh", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "apellis_big.png", "image2id": "apellis_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Rare diseases", "topic_tag": "Drug Trial, One to Watch Companies, Research", "geography_tag": "Sweden, USA", "company_tag": "Apellis Pharmaceuticals, Swedish Orphan Biovitrum", "drug_tag": "Empaveli, pegcetacoplan", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 16:42:00"}